|
CHTF8 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.35367281220533E-14 |
| Normal-vs-Stage2 |
7.26180000021337E-07 |
| Normal-vs-Stage3 |
4.03010957938932E-14 |
| Normal-vs-Stage4 |
1.64213087572307E-12 |
| Stage1-vs-Stage2 |
4.584800E-01 |
| Stage1-vs-Stage3 |
1.916610E-01 |
| Stage1-vs-Stage4 |
1.020270E-02 |
| Stage2-vs-Stage3 |
1.312800E-01 |
| Stage2-vs-Stage4 |
1.294090E-02 |
| Stage3-vs-Stage4 |
1.393390E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
9.99200722162641E-16 |
| Normal-vs-AfricanAmerican |
5.78890000046961E-07 |
| Normal-vs-Asian |
1.87100002158047E-10 |
| Caucasian-vs-AfricanAmerican |
7.682600E-01 |
| Caucasian-vs-Asian |
6.594200E-01 |
| AfricanAmerican-vs-Asian |
5.500200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.90909526970518E-13 |
| Normal-vs-Female |
1.62492241884138E-12 |
| Male-vs-Female |
4.524200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.84807724679104E-12 |
| Normal-vs-Age(41-60Yrs) |
2.19602114270856E-13 |
| Normal-vs-Age(61-80Yrs) |
1.75537362423484E-12 |
| Normal-vs-Age(81-100Yrs) |
1.021400E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.459800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.893400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.977200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.935200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.494000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.395800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.218130E-02 |
| Classical-VS-Follicular |
8.146000E-01 |
| Classical-VS-Other |
1.688610E-01 |
| Classical-VS-Normal |
1.62503344114384E-12 |
| Tall-VS-Follicular |
3.687700E-02 |
| Tall-VS-Other |
9.415400E-01 |
| Tall-VS-Normal |
5.81978909508507E-12 |
| Follicular-VS-Other |
3.425600E-01 |
| Follicular-VS-Normal |
4.6571000389406E-09 |
| Other-VS-Normal |
8.0040000000059E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.67184060934278E-12 |
| Normal-vs-N1 |
1.11022302462516E-16 |
| N0-vs-N1 |
7.55829999999902E-05 |
|
|
